Economic Impact of a Rotavirus Vaccine in Brazil

Dagna O. Constenla¹, Alexandre C. Linhares², Richard D. Rheingans¹, Lynn R. Antil¹, Eliseu A. Waldman³, and Luiz J. da Silva⁴

¹Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA, ²Seção de Virologia, Instituto Evandro Chagas, Secretaria de Vigilância em Saúde, Ministério da Saúde, Av. Almirante Barroso 492, 66090-000 Belém, Pará, Brasil, ³Departamento de Epidemiologia, Faculdade de Saúde Pública, Universidade de São Paulo, São Paulo, SP 01246-904, Brasil, and ⁴Disciplina de Infectologia, Departamento de Clínica Médica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, 13083-970, Brasil

ABSTRACT

The study was done to evaluate the cost-effectiveness of a national rotavirus vaccination programme in Brazilian children from the healthcare system perspective. A hypothetical annual birth-cohort was followed for a five-year period. Published and national administrative data were incorporated into a model to quantify the consequences of vaccination versus no vaccination. Main outcome measures included the reduction in disease burden, lives saved, and disability-adjusted life-years (DALYs) averted. A rotavirus vaccination programme in Brazil would prevent an estimated 1,804 deaths associated with gastroenteritis due to rotavirus, 91,127 hospitalizations, and 550,198 outpatient visits. Vaccination is likely to reduce 76% of the overall healthcare burden of rotavirus-associated gastroenteritis in Brazil. At a vaccine price of US$ 7-8 per dose, the cost-effectiveness ratio would be US$ 643 per DALY averted. Rotavirus vaccination can reduce the burden of gastroenteritis due to rotavirus at a reasonable cost-effectiveness ratio.

Key words: Costs and cost analysis; Diarrhoea, Infantile; Gastroenteritis; Morbidity; Rotavirus; Rotavirus vaccines; Vaccination; Brazil

INTRODUCTION

Rotavirus can lead to severe life-threatening gastroenteritis in infants and young children worldwide. Unlike many other enteropathogens, rotavirus affects children in both developed and developing countries (1-2) and is not associated with socioeconomic factors. However, the risk of dying from severe rotavirus-associated infection is higher in lower-income countries due to various factors, including limited access to healthcare facilities, malnutrition, earlier onset of infection, and mixed infections involving rotavirus and other pathogens. Rotavirus infects most children by three years of age, and prevention of rotavirus spread is virtually impossible, even in environments with the highest hygiene measures (2). Improvements in the availability of safe water and sanitation, access to oral rehydration therapy, and higher vaccine coverage have reduced the overall burden of gastroenteritis in children (3-4). From 1980 to 2002, Brazil showed a decrease by 91.5% in mortality due to gastroenteritis among children aged less than five years (3-4). During the same period, the proportion of infant deaths attributed to gastroenteritis fell from 41% to 4.7%, but with a range of 2.1% in the Southeast region to 7.8% in the Northeast (3-4). Infant mortality decreased from 85.2 per 1,000 children in 1980 to 25.1 per 1,000 children in 2002 (3-4).

Two surveys conducted in São Paulo in 1984-1985 and 1995-1996, including representative samples of the population aged 0-59 month(s), reported an overall reduction in the point prevalence of gastroenteritis from 1.7% to 0.9%, and a reduction in hospitalization due to gastroenteritis from 2.21 to 0.79 per 100 children-years (5). The latest survey (1995-1996) reported a 4.7% period prevalence of gastroenteritis when inquired about diarrhoea during the last two weeks (5). In contrast, a third survey carried out in the metropolitan area of Recife (Northeast region) in 1997 reported a 5.6% point prevalence of gastroenteritis and a period prevalence of 16.9% when inquired about diarrhoea during the last two weeks (6).
Despite improvements in health conditions among Brazilian children aged less than five years, gastroenteritis remains a significant burden in children in this age-group. In 2002, gastroenteritis caused about 3,000 deaths across the country, representing a rate of 19.6 deaths per 100,000 children aged less than five years, with a range of 34.2-7.6 deaths per 100,000 children in the Northeast and the Southeast respectively. Of the total deaths in children aged less than five years, infants were the most vulnerable group, with 81.8% of all deaths due to gastroenteritis (7).

Several studies have focused on the occurrence of acute diarrhoea associated with outpatient clinic visits and hospitalizations, yielding average prevalence rates that ranged from 12% to 42% throughout the country (8). An official nationwide surveillance system has been implemented through the Brazilian Health Ministry to determine the overall burden of rotavirus-associated disease and to monitor strain diversity. In March 2006, the Brazilian Health Ministry made available an attenuated vaccine against rotavirus-associated gastroenteritis for universal use in the country.

In this paper, we report the burden of disease and costs of gastroenteritis due to rotavirus in Brazilian children and the expected cost-effectiveness of a national rotavirus vaccination programme. The results presented here are based on a major study conducted in the region (9-10). Country-level estimates were used in the present analysis, and findings differ from the earlier study. In addition, this paper considers information on the recent introduction of the vaccine in the public sector in Brazil, including its cost.

**MATERIALS AND METHODS**

**Model overview**

A model was developed to estimate the disease outcomes and costs associated with gastroenteritis due to rotavirus in a hypothetical annual birth-cohort of children for a five-year period. The performance of the vaccination strategy is described using incremental cost-effectiveness ratios, defined as the additional cost of a specific strategy, divided by its additional benefit, compared with the next most costly strategy. Results are presented in US dollar (as in 2003) for local and regional decision-makers. Future costs and disability-adjusted life-year (DALY) estimates were discounted at an annual 3% rate as recommended by the US Panel of Cost-effectiveness in Health and Medicine (11) and the World Bank Global Burden of Disease Project (12). Model outcomes included averted hospitalizations, outpatient visits, deaths and DALYs, and costs. Costs, such as non-medical direct costs (transportation costs) or productivity losses to caregivers, were not included in the cost-effectiveness calculations; however, they were presented in the cost calculations.

The annual birth-cohort considered in the model included 3,471,000 children aged less than five years (13). The age distribution of rotavirus-associated disease was estimated for each of the disease outcomes using published findings of studies from Brazil and the Latin American region (14-23).

**Rotavirus-associated disease and economic burden**

The burden of disease was estimated as the expected number of rotavirus-associated events (hospitalizations, outpatient visits, and deaths) during the first five years of life for a single birth-cohort. The risk of rotavirus-associated events were based on the cumulative risk of each event due to acute gastroenteritis during the first five years of life and the proportion of these events attributed to rotavirus. Detailed explanation of the methods used for estimating the burden of disease in Brazil can be found elsewhere (10).

In addition to estimating numbers of hospitalizations, outpatient visits and deaths, the burden of disease was also expressed in terms of DALYs (12). DALYs provide a standardized measure of the burden of disease that allows for cross-comparisons of the burden of disease and comparison with other diseases. The DALY estimate included years of life lost due to premature mortality and years lived with disability. The DALY loss from mortality was calculated based on the average country-specific life expectancy at zero and one year of age using life tables reported by the World Health Organization (WHO) (24). The average life expectancy for males and females is 68.2 at birth and 69.7 at one year of age. For the calculation of years lived with disability, only morbidity from disease severe enough to require medical care was considered. Default disability weights from the Global Burden of Disease Study (12), the WHO guidelines for cost-effectiveness studies (25), and estimated rotavirus illness duration of six days (26) were used in calculating years lived with disability. DALYs calculated reflect the disability weight and duration estimates for gastroenteritis due to rotavirus as provided in the Global Burden of Disease Study (12). This calculation is age-weighted (25) and uses an annual discount rate of 3%.
The economic burden of rotavirus-associated gastroenteritis for Brazil was estimated by combining estimates of the number of each type of event with information on the costs associated with the event. Country-specific estimates of healthcare costs were developed for hospital and outpatient rotavirus-associated events. In addition to healthcare costs, transportation costs to healthcare facilities were also included in the calculations of costs. For the base case analysis, these costs were based on assumptions made about the number of trips to and from the doctor’s office and/or the hospital and the cost of each trip. The number of trips to and from the doctor’s office and/or hospital was based on the amount of outpatient visits and hospital admissions reported by physicians in a multicentre hospital-based rotavirus surveillance study (Abate H, Linhares AC, Venegas G, Vergara R, Lopez, P, Jimenez E et al. Results of a hospital-based study of rotavirus gastroenteritis in Latin American children. Resumen presentado en el Congreso Internacional de Pediatría en Cancún, México, 15-20 de agosto de 2004. Unpublished) conducted in Belem. These estimates were considered to be the most reliable estimates for Brazil. Indirect costs associated with lost time from paid work were also calculated. For the base case analysis, these costs were based on the number of days off from work (one outpatient consultation or one day in the hospital was assumed to be the same as one day off from work), assuming an average 2003 minimum monthly salary in Brazil and 22 days off from work. A complete description of the methods used in calculating the economic burden was reported elsewhere (10).

Effectiveness of vaccination and costs

Estimates of the effectiveness of rotavirus vaccination were based on the results of clinical trials of human rotavirus vaccine administered orally to infants at two and four months of age (27-28). The vaccine demonstrated an 85% efficacy in preventing hospitalizations for gastroenteritis due to rotavirus (27). Efficacy in averting deaths was assumed to be the same as that for hospitalized cases (85%). No data on specific efficacy are available for outpatient visits. Therefore, rates for the episodes of severe gastroenteritis due to rotavirus were considered (84.7-86%) to be rotavirus-associated gastroenteritis (27-28). For the baseline analysis, the efficacy of one dose was assumed to be 62.5% [95% confidence interval (CI) (16-83)] (López P, Linhares AC, Pérez-Schael I, Ruiz-Palacios GM, Costa-Clemens SA, Sanchez N et al. Early protection against severe rotavirus gastroenteritis—RIX4414 experience in Latin America. European Society of Paed Infect Dis Congress, May 3-5 2003, Basel, Switzerland. Unpublished). It was further assumed that efficacy would not decline in the second year (Linhares. Personal communication, 2007) and subsequent years following vaccination.

We assumed that children would receive the vaccine to prevent rotavirus-associated gastroenteritis at the time of the diphtheria-tetanus-pertussis-hepatitis B virus- Haemophilus influenzae vaccine (DTPwHBV/Hib) and the oral polio virus vaccine (OPV) in Brazil, which are given at two, four, and six months of age. In the baseline analysis, the national coverage of the third dose of DTPw at one year of age for 2003 was estimated to be 96% (29). Rotavirus vaccination would occur with DTPwHBV/Hib and OPV doses (one and two); however, standardized data are only available for the coverage of the third dose.

In this analysis, we included the cost of administration of the vaccine, the price of each dose, the number of doses given (based on coverage level), and expected losses from waste (10%). The costs for administering the vaccine included the cost of healthcare personnel and training, cold-chain, storage space, and public education. Brazil has the necessary infrastructure for running a national rotavirus vaccination programme, based on its extensive history of administering oral polio vaccine. Therefore, the incremental administration costs are assumed to be low. A few studies estimated the cost of immunization for current EPI vaccines (30-33); however, no data on the incremental cost of adding a vaccine to the current EPI regimen were found. Based on the range of estimates found in studies conducted on the immunization cost and the assumption of low incremental costs, the model assumes the cost for administering the vaccine as US$ 0.50 per dose. The Brazilian Ministry of Health purchased the vaccine at a cost of US$ 7-8 per dose and made it available for the public sector in March 2006.

Table 1 summarizes the best estimates used in the analysis.

Sensitivity analyses

One-way sensitivity analyses were done by calculating the main outcomes, the economic burden, and cost-effectiveness, for different scenarios that are likely to influence the costs of rotavirus-associated disease and the cost-effectiveness of a vaccination programme. These scenarios included: high and
low end-estimates of outpatient visits, hospitalization and mortality rates, vaccine efficacy against hospitalizations and death, hospital per diem, cost of outpatient visit, and price of vaccine.

**RESULTS**

**Burden of disease**

Table 2 shows the projected disease outcomes of rotavirus in Brazil under current treatment (no vaccination) and with rotavirus vaccination. By the age of five years, one in five (205 per 1,000) children required a clinic visit for rotavirus-associated gastroenteritis, one in 29 (35 per 1,000) children was hospitalized for gastroenteritis due to rotavirus, and one in 1,429 (0.7 per 1,000) children died due to rotavirus-associated gastroenteritis. An estimated 24 DALYs per 1,000 births were lost from these outcomes. This compares with the rates observed in other countries in the region where rates of rotavirus-associated mortality are low (34-35). For the base case, the model predicts that a total of 550,198 outpatient-visits (159 per 1,000), 91,127 hospitalizations (26 per 1,000), and 1,804 deaths
Constenla DO et al.

Economics of rotavirus vaccine in Brazil

JHPN

392

(0.52 per 1,000) associated with gastroenteritis due to rotavirus would be prevented by rotavirus vaccination. This represents an overall reduction of 77%, 76%, and 73% respectively.

Costs of events due to rotavirus-associated gastroenteritis

Estimates of the direct medical costs, direct non-medical costs, and indirect costs for inpatients and outpatients with gastroenteritis are provided in Table 3 and are based on the hospital-based surveillance. The total direct medical cost for inpatients was US$ 150.97, with 86% of the cost attributed to the hospital stay and the remainder due to the cost of diagnostics and medication. For outpatients, the total direct medical cost was only US$ 10.81, of which 50% is attributed to the cost of the visit.

Forty-four percent of caregivers reported that they paid to visit the child at the hospital. For all caregivers (including those who did not report payment per visit), the mean cost to transport child to the hospital was US$ 1.49. This was multiplied by the mean number of trips (8.58) for a total of US$ 12.78 per child. For outpatients, 6% of caregivers reported that they paid to visit the child at the outpatient clinic. Of those who paid, the median cost to transport the child was US$ 0.04. This was multiplied by the mean number of trips (0.5) for a total of US$ 0.02 per child.

Table 2. Estimated burden of rotavirus in Brazil with and without vaccination programme

| Type of event | Total events | Events per 1,000 children |
|---------------|--------------|--------------------------|
| Current management (without vaccination) | | |
| Hospitalizations | 120,513 | 34.72 |
| Outpatient visits | 712,249 | 205.20 |
| Deaths | 2,475 | 0.71 |
| DALYs* | 83,365 | 24.02 |
| With vaccination | | |
| Hospitalizations | 29,386 | 8.47 |
| Outpatient visits | 162,051 | 46.69 |
| Deaths | 671 | 0.19 |
| DALYs* | 22,671 | 6.53 |
| Benefit of vaccination (averted events)† | | |
| Hospitalizations | 91,127 | 26.25 |
| Outpatient visits | 550,198 | 158.51 |
| Deaths | 1,804 | 0.52 |
| DALYs* | 60,694 | 17.49 |

*Discounted at 3%; †Benefit of vaccination is based on the vaccine effectiveness, which incorporates information on the vaccine efficacy and coverage; DALYs=Disability-adjusted life-years

Table 3. Costs of treating gastroenteritis in Brazil estimated from hospital-based surveillance data*

| Variable | Inpatients (n=43)† | Outpatients (n=52)† |
|----------|-------------------|---------------------|
| Cost per stay/visit (US$) | 129.76 | 5.39 |
| Medications (US$) | 14.47 | 4.87 |
| Diagnostics (US$) | 6.74‡ | 0.55 |
| Total direct medical costs (US$) | 150.97‡ | 10.81 |
| Percentage who paid to visit child | 44 | 6 |
| Payment to visit child (US$) | 1.49‡ | 0.04‡ |
| Mean number of trips | 8.58 | 0.5 |
| Non-medical direct costs (US$) | 12.78‡ | 0.02‡ |
| (transport) | | |
| Percentage who lost time from work | 53 | 48 |
| Hours lost from work | 28.90¶ | 19.92¶ |
| Average female hourly wage (US$) | 1.45§ | 1.45§ |
| Indirect costs (US$) | 41.90 | 28.88 |
| Total cost per patient (US$) | 205.65 | 39.71 |

*10 sites participated in the health economic component of the hospital-based surveillance study: 2 secondary-level hospitals, 5 primary healthcare units (Unidades Basicas de Saude [postos de saúde]), 2 private healthcare units (emergency rooms linked to tertiary-level hospitals), and one Unidad del Programa de Familia Saludable; †Cost data are based on US$ as in 2003; ‡Missing one value; ¶Median value calculated for those parents who indicated they lost time from work; §This value assumes an eight-hour shift.
The indirect cost associated with lost wages for inpatients was more than that for outpatients (US$ 41.9 vs US$ 28.9) because the percentage of subjects who lost time from work was higher for caregivers of inpatients than outpatients (53% vs 48%) and, on average, caregivers of inpatients lost more time from work than outpatients (28.9 hours vs 19.9 hours).

Table 4 shows the estimated healthcare costs per birth-cohort from these rotavirus-associated events in Brazil. In the absence of vaccination, it is estimated that rotavirus-associated gastroenteritis results in a total healthcare cost of over US$ 25.3 million for each annual birth-cohort in Brazil, which is equivalent to US$ 7.30 per child. Seventy percent of these costs are associated with hospitalization. Vaccination is likely to reduce the economic burden of gastroenteritis due to rotavirus significantly in Brazil, averting US$ 19.3 million (76% of the total healthcare cost).

Cost-effectiveness of a rotavirus vaccination programme

The expected costs and benefits of a rotavirus vaccination programme in Brazilian children are presented in Table 5. Results shown here are for a single birth-cohort, assuming 96% coverage and a basic vaccine price of US$ 7-8 per dose. Costs of the vaccination include the cost of the vaccine and its administration. Moreover, vaccination cost assumes only the cost of vaccinating children who would receive the vaccine, based on vaccine coverage estimates and 10% wastage. Benefits are expressed as net medical costs from the healthcare system perspective and the cost-effectiveness ratio. All of these cost and benefit measures vary directly with the vaccine price.

| Vaccine programme cost | Amount (US$) |
|------------------------|--------------|
| Vaccine administration  | 3,332,160    |
| Vaccine (US$ 7-8/dose)  | 54,980,640   |
| Total                  | 58,312,800   |
| Net medical direct cost| 39,044,331   |

Incremental cost-effectiveness ratio

- Cost per DALY: 643
- Cost per life saved: 21,643
- Cost per hospitalization averted: 428
- Cost per medical visit averted: 70

At a price of US$ 7-8 per dose, the net medical cost for the healthcare system to vaccinate the Brazilian birth-cohort with the rotavirus vaccine would be US$ 39 million. From the healthcare perspective, a rotavirus vaccination costs US$ 643 per DALY averted, US$ 21,643 per life saved, US$ 428 per hospitalization averted, and US$ 70 per medical visit averted. The vaccination programme would be considered cost-saving to the healthcare system at a vaccine price lower than US$ 2.17 per dose. Higher vaccine prices require a net economical investment but provide a health benefit.

Sensitivity analysis

The estimated medical cost per child is most sensitive to changes in assumptions regarding the incidence of hospitalization due to rotavirus and the cost of hospital treatment. A 25% change in either
of those parameters results in a 12-15% change in the medical cost per child. The estimates of incremental cost-effectiveness rate are affected by the rotavirus-associated mortality rate, efficacy of vaccine against mortality, and vaccine price. A 25% change in any of these variables results in 15-40% change in the incremental cost-effectiveness ratio. Overall, an increase in the incidence of rotavirus and efficacy of vaccine will result in a lower incremental cost-effectiveness ratio making a vaccination programme more cost-effective. Furthermore, a reduction in the price of rotavirus vaccination (US$ 5 per dose) will yield a lower incremental cost-effectiveness ratio of US$ 341 per DALY averted, making the vaccine even more cost-effective.

**DISCUSSION**

This is the first time a national rotavirus vaccination programme is evaluated in Brazil in economic terms. Rotavirus-associated gastroenteritis is a common disease with an estimated 832,762 cases of gastroenteritis due to rotavirus and 2,475 deaths occurring annually in Brazil. The large burden of outpatient visits due to rotavirus-associated gastroenteritis is a significant contributor to the substantial costs in the healthcare system.

Vaccination provides an effective opportunity for improving children’s health in Brazil. We estimated that vaccination would prevent more than three-fourths of all cases due to rotavirus-associated gastroenteritis, including 1,804 deaths. This translates into almost one life saved and 185 cases prevented per 1,000. We also estimated that vaccination would result in total medical savings of US$ 19.3 million. At the current vaccine price of US$ 7-8 per dose, vaccination would be cost-effective from the perspective of the healthcare system based on the WHO benchmarks for cost-effectiveness.

It is important to emphasize that even if vaccination appears to be cost-effective according to a criterion of the cost-effectiveness ratio being less than the per-capita GDP of Brazil, it may not be affordable. Even an intervention that provides good value for resources invested may have prohibitive financial requirements that could not be accommodated by the healthcare system of Brazil.

Limitations of this analysis include, but are not limited to, uncertainties around the epidemiology of gastroenteritis due to rotavirus in Brazil and efficacy of vaccine against death. Moreover, the actual proportion of diarrhoeal deaths due to rotavirus is unknown. Efforts should be made to ascertain the incidence of deaths due to rotavirus-associated gastroenteritis using active surveillance studies, especially in regions of the country where there may be limited access to emergency treatment facilities.

Another limitation is related to the coverage rate and/or timing of vaccination. The coverage is based on the coverage of other vaccines, e.g. DTP+HepB/ Hib and OPV, which may not be an accurate estimation of coverage for the current rotavirus vaccine. In the analysis, we assumed that all groups within the country have equal likelihood of vaccination, and all children would receive the vaccine at the recommended time. If high-risk populations were missed or vaccination was delayed, the effectiveness would be reduced. Since rotavirus-associated gastroenteritis occurs in young children and protection is conferred from the time of vaccine dose 1 until dose 2 is given (29), it is important that the vaccine be given on time; this is the scenario adopted in the health economic model used for this analysis. Future considerations should be made to account for the fact that not all children will receive the vaccine at the recommended time.

A final limitation is the lack of data on the magnitude of herd immunity which may be conferred by the partial coverage of vaccination into a population. The analysis considered the direct effects of vaccination, but it did not consider the indirect protective effect on persons never vaccinated. The herd immunity effect could be large and might offset inefficiencies in the delivery of a complete course and vaccination on time to all children. This analysis supports the conclusion that gastroenteritis due to rotavirus poses a sizeable burden in Brazil and results in 120,513 hospitalizations, 712,249 outpatient visits, 2,475 deaths, and 83,365 DALYs annually in Brazil. At a price per dose of US$ 7-8 for Brazil, the cost per DALY averted is less than US$ 700. This ratio is less than per-capita GDP of Brazil, but more importantly, it compares favourably with the ratios of other vaccines (36). For example, the cost-effectiveness of pneumococcal conjugate vaccination ranged from US$ 110 to US$ 2,150 across a range of countries (37-38); rotavirus vaccination ranged from US$ 290 to US$ 12,300 in Latin American countries (9,34-35,39-40); and influenza vaccination was cost-saving in high-risk children in Argentina (41).

**ACKNOWLEDGEMENTS**

Funding for the study was provided by GlaxoS-mithKline Biologicals. Full independence of methods and control over publication remain with the
authors along with responsibility for any errors. The authors thank the following experts for their assistance in identifying epidemiological data and their general support for the study: Alfredo Gilio (Diretor da Divisão de Pediatría, Clínica de Hospital Universitário, São Paulo); Expedito Luna (Diretor, Departamento de Vigilância Epidemiológica, Brasilia); Divina das Dôres de Paula Cardoso and Paulo da Costa (Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Goiás); Marcos Bosi Ferraz (Centro Paulista de Economia da Saúde, São Paulo); and Nilo Serpa (Analista de Sistemas, Secretaria de Saúde do Estado de Rio de Janeiro).

REFERENCES

1. Bree JS, Glass RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. *Vaccine* 1999;17:2207-22.

2. Kapikian AZ, Hoshino Y, Chanok RM. R Ves. Philadelphia: Lippincott, 1993:178-834.

3. Victora C, Barros F. Diarrheal disease among children under five years in the Americas, 1980-1992. New York, NY: United Nations Children’s Fund, 1993. 230 p.

4. Brasil. Ministério da Saúde. Departamento de Análise de Situação de Saúde/SVS. Indicadores de dados básicos para a saúde. Brasília, D.F.: Ministério da Saúde, 2004. 280 p.

5. Benício MHD e Monteiro CA. Tendência secular da doença diarréica na infância nas cidades de São Paulo (1984-1996). *Rev Saúde Pública* 2000;34(Suppl 6):S83-90.

6. Instituto Nacional de Alimentação e Nutrição. Tendência secular da doença diarréica na infância e na infância entre 1986 e 2000. Brasília, D.F.: Ministério da Saúde, 1998. 189 p.

7. Brasil. Ministério da Saúde. Departamento de Análise de Situação de Saúde/SVS. Sistema de informações sobre mortalidade. Brasília, D.F.: Ministério da Saúde, 2004. 460 p.

8. Linhares AC, Bree JS. Rotavirus vaccines and vaccination in Latin America. *Rev Panam Salud Publica* 2000;8:305-31.

9. Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. *Rev Panam Salud Publica* 2007;21:205-16.

10. Rheingans RD, Constenla D, Antil L, Innis B, Breuer T. Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries. *Rev Panam Salud Publica* 2007;21:192-204.

11. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996. 456 p.

12. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press, 1996. 1,022 p.

13. Pan-American Health Organization. Health analysis and Information systems area. Regional core health data initiative; technical health information system. Washington, DC: Pan-American Health Organization, 2004. 18 p. (http://www.paho.org/English/SHA/coredata/tabulator/newTabulator.htm, accessed on 4 September 2003).

14. Barraza P, Avendaño LF, Spencer E, Calderón A, Prenzel I, Duarte E. Hospital infection caused by rotavirus in infants, Santiago, Chile. *Bol Oficina Sanit Panam* 1986;101:328-38.

15. Bok K, Castagnaro NC, Diaz NE, Borsa A, Cagnoli MR, Nates S et al. Rotavirus laboratory network: results after one year of observation. *Rev Argent Microbiol* 1999;31:1-12.

16. Bok K, Castagnaro N, Borsa A, Nates S, Espul C, Fay O et al. Surveillance for rotavirus in Argentina. *J Med Virol* 2001;65:190-8.

17. Cardoso DDP, Soares CMA, Dias e Souza MB, de Azevedo Mda S, Martins RM, Queirazá DA et al. Epidemiological features of rotavirus infection in Goiania, Goias, Brazil, from 1986 to 2000. *Mem Inst Oswaldo Cruz* 2003;98:25-9.

18. Gomez JA, Sordo ME, Gentile A. Epidemiologic patterns of diarrheal disease in Argentina: estimation of rotavirus disease burden. *Pediatr Infect Dis J* 2002;21:843-50.

19. González FS, Sordo ME, Rowensztein G, Sabbag L, Roussos A, De Petre E et al. Rotavirus diarrhea. Impact in a pediatric hospital of Buenos Aires. *Medicina* (B Aires) 1999;59:321-6.

20. Pérez-Schael I, González R, Fernández R, Alfonzo E, Inaty D, Boher Y et al. Epidemiological features of rotavirus infection in Caracas, Venezuela: implications for rotavirus immunization programs. *J Med Virol* 1999;59:520-6.

21. Urrestarazu MI, Liprandi F, Pérez de Suárez E, González R, Pérez-Schael I. Etiologic, clinical, and socio-demographic characteristics of acute diarrhea in Venezuela. *Rev Panam Salud Publica* 1999;6:149-56.
22. Velázquez FR, Matson DO, Guerrero ML, Shults J, Calve JJ, Morrow AL et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000;182:1602-9.
23. Villa S, Guiscafré H, Martínez H, Muñoz O, Gutiérrez G. Seasonal diarrhoeal mortality among Mexican children. Bull World Health Organ 1999;77:375-80.
24. Lopez AD, Salomon J, Ahmad O, Murray CJL, Mafiga D. Life tables for 191 countries: data, methods and results. Geneva: World Health Organization, 2000. 254 p. (GPE discussion paper no. 9).
25. Baltussen R, Adam T, Tan Torres T, Hutubessy R, Acharya A, Evans D et al. Generalized cost effectiveness analysis: a guide. Geneva: World Health Organization, 2002. 329 p.
26. Liddle JL, Burgess MA, Gilbert GL, Hanson RM, McIntyre PB, Bishop RF et al. Rotavirus gastroenteritis: impact on young children, their families, and the health care system. Med J Aust 1997;167:304-7.
27. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22.
28. Salinas B, Pérez-Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzábal JP et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Ped Infect Dis J 2005;24:807-16.
29. World Health Organization. WHO & UNICEF estimates of national immunization coverage, 2003. 10 p. (http://www.who.int/vaccines_surveillance/WHOUNICEF_CoverageReview/, accessed on 11 October 2004).
30. Brenzel L, Claquin P. Immunization programs and their costs. Soc Sci Med 1994;39:527-36.
31. Miller MA, McCann L. Policy analysis of the use of hepatitis B, haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ 2004;9:19-35.
32. Walker D, Mosqueda NR, Penny ME, Lanata CF, Clark AD, Sanderson CF et al. Variation in the costs of delivering routine immunization services in Peru. Bull World Health Organ 2004;82:676-82.
33. Waters HR, Dougherty L, Tegang SP, Tran N, Wysonge CS, Long K et al. Coverage and costs of childhood immunizations in Cameroon. Bull World Health Organ 2004;82:668-75.
34. Constenla D, O’Ryan M, Navarrete MS, Antil L, Rheingans RD. Potential cost effectiveness of a RV vaccine in Chile. Rev Méd Chile 2006;134:679-88.
35. Constenla D, Pérez-Schael I, Rheingans RD, Antil L, Salas H, Yarzábal JP. Evaluación del impacto económico de la vacuna antirrotavirica en Venezuela. [Assessment of the economic impact of the antiretroviral vaccine in Venezuela]. Rev Panam Salud Pública 2006;20:213-22 [Spanish].
36. World Health Organization. Macroeconomics and health: investing in health for economic development: report of the commission on macroeconomics and health. Geneva: World Health Organization, 2001. 210 p.
37. Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007;369:389-96.
38. Constenla D. Evaluating the cost-effectiveness of a pneumococcal conjugate vaccination program in selected Latin American countries. Rev Panam Salud Pública 2008 (in press).
39. Constenla D, Ortega-Barría E, Rheingans R, Antil L, Sáez-Llorens X. Impacto económico de la vacuna antirrotavirica en Panamá [Economic impact of rotavirus vaccination in Panama]. An Pediat (Barc) 2008;68:128-35 [Spanish].
40. Constenla D, Rivera M, Rheingans RD, Antil L, Vásquez ML. Evaluación económica de una eventual incorporación de la vacuna anti-rotavirus en el calendario de vacunación infantil en Honduras. Rev Med Hond 2006;74:19-29.
41. Dayan GH, Nguyen VH, Debbag R, Gómez R, Wood SC. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 2001;19:4204-13.